Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

20071,996 citationsJournal Article

Authors

Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 25, Issue 13, pp. 1658-1664

Field-Weighted Citation Impact: 84.64